MIRA Pharmaceuticals Inc MIRA
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-08-03 |
| Shares Out. | 42,020,000 |
| Website | mirapharmaceuticals.com/ ↗ |
| Phone | 18133695150 |
| Employees | 2 |
| Net Income | -$1.2M |
| Total Assets | $9.5M |
| Total Liabilities | $114,761 |
| Equity | $9.3M |
About MIRA Pharmaceuticals Inc
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
MIRA Pharmaceuticals Inc is a publicly traded company under the ticker symbol MIRA on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-05-01)